MDT

87.11

-0.93%↓

A

115.09

-0.3%↓

VEEV

151.46

-3.57%↓

HQY

78.12

-6.83%↓

TLRY

6.58

-1.94%↓

MDT

87.11

-0.93%↓

A

115.09

-0.3%↓

VEEV

151.46

-3.57%↓

HQY

78.12

-6.83%↓

TLRY

6.58

-1.94%↓

MDT

87.11

-0.93%↓

A

115.09

-0.3%↓

VEEV

151.46

-3.57%↓

HQY

78.12

-6.83%↓

TLRY

6.58

-1.94%↓

MDT

87.11

-0.93%↓

A

115.09

-0.3%↓

VEEV

151.46

-3.57%↓

HQY

78.12

-6.83%↓

TLRY

6.58

-1.94%↓

MDT

87.11

-0.93%↓

A

115.09

-0.3%↓

VEEV

151.46

-3.57%↓

HQY

78.12

-6.83%↓

TLRY

6.58

-1.94%↓

Search

CareDx Inc

Closed

SectorHealthcare

16.03 -1.54

Overview

Share price change

24h

Current

Min

15.55

Max

16.89

Key metrics

By Trading Economics

Income

-5.8M

-4.1M

Sales

8.3M

108M

P/E

Sector Avg

14.645

66.418

EPS

0.12

Profit margin

-3.79

Employees

761

EBITDA

-5.7M

1.5M

Recommendations

By TipRanks

Recommendations

Buy

12 Months Forecast

+49.79% upside

Dividends

By Dow Jones

Next Earnings

29 kwi 2026

Market Stats

By TradingEconomics

Market Cap

-84M

917M

Previous open

17.57

Previous close

16.03

News Sentiment

By Acuity

30%

70%

110 / 348 Ranking in Healthcare

Technical Score

By Trading Central

Confidence

Neutral Evidence

CareDx Inc Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

10 kwi 2026, 17:04 UTC

Major Market Movers

FDA Rejects Replimune's Melanoma Drug for a Second Time

11 kwi 2026, 00:00 UTC

Earnings
Acquisitions, Mergers, Takeovers

Big Yachts, Big Bucks -- Barrons.com

10 kwi 2026, 21:55 UTC

Acquisitions, Mergers, Takeovers

Paramount Warrants Are an Underappreciated Aspect of Warner Bros. Deal -- Barrons.com

10 kwi 2026, 21:01 UTC

Earnings

Cango Inc.: Files Annual Report on Form 20-F With SEC

10 kwi 2026, 20:50 UTC

Market Talk

Energy & Utilities Roundup: Market Talk

10 kwi 2026, 20:50 UTC

Market Talk
Major News Events

Basic Materials Roundup: Market Talk

10 kwi 2026, 20:50 UTC

Market Talk

Health Care Roundup: Market Talk

10 kwi 2026, 20:31 UTC

Market Talk

Convenience Store Traffic Slows as Gas Prices Rise -- Market Talk

10 kwi 2026, 20:10 UTC

Acquisitions, Mergers, Takeovers

This Women's Health Company Is Drawing Takeover Interest. The Stock Is Soaring. -- Barrons.com

10 kwi 2026, 19:15 UTC

Market Talk

Global Energy Roundup: Market Talk

10 kwi 2026, 19:15 UTC

Market Talk

Oil Futures Settle Lower With Focus on U.S.-Iran Talks -- Market Talk

10 kwi 2026, 19:08 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

10 kwi 2026, 19:08 UTC

Market Talk

U.S. Natural Gas Futures End Week Lower -- Market Talk

10 kwi 2026, 18:38 UTC

Market Talk

Canada's Job Market Showing Soft Demand, Structural Decline in Supply -- Market Talk

10 kwi 2026, 18:25 UTC

Market Talk
Major News Events

Precious Metals Finish With Weekly Gains -- Market Talk

10 kwi 2026, 18:05 UTC

Market Talk

Rising Commodity Prices Seen Carrying More Weight Than Jobs Data for Bank of Canada Watchers -- Market Talk

10 kwi 2026, 17:31 UTC

Market Talk
Major News Events

U.S. Oil Rig Count Unchanged This Week At 411 -- Market Talk

10 kwi 2026, 17:26 UTC

Earnings

Big Banks' Profits Set to Rise Even as 'Wall of Worry' Looms -- Barrons.com

10 kwi 2026, 17:10 UTC

Market Talk

White House Defense of Stablecoin Yields Is Welcome Move, Grayscale Says -- Market Talk

10 kwi 2026, 17:00 UTC

Major News Events

Construction Business Taking a Hit From Iran Conflict -- WSJ

10 kwi 2026, 16:20 UTC

Market Talk

Health Care Roundup: Market Talk

10 kwi 2026, 16:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

10 kwi 2026, 16:12 UTC

Earnings

Partners Group CEO: Group Well Positioned to Navigate Current Complex Environment

10 kwi 2026, 16:11 UTC

Earnings

Partners Group: Traditional Programs Contributed $3.3B

10 kwi 2026, 16:10 UTC

Earnings

Partners Group: $5B of New Commitments Came From Bespoke Solutions

10 kwi 2026, 16:10 UTC

Earnings

Partners Group: That Is Across All Private Markets Asset Classes and Client Strategies

10 kwi 2026, 16:10 UTC

Earnings

Partners Group 1Q New Client Demand $8.3B

10 kwi 2026, 16:09 UTC

Earnings

Partners Group Continued to See Positive Fundraising Momentum in 1Q

10 kwi 2026, 15:54 UTC

Acquisitions, Mergers, Takeovers

Plenitude Completes Acquisition of Acea Energia

10 kwi 2026, 15:38 UTC

Market Talk

Global Energy Roundup: Market Talk

Peer Comparison

Price change

CareDx Inc Forecast

Price Target

By TipRanks

49.79% upside

12 Months Forecast

Average 25 USD  49.79%

High 28 USD

Low 21 USD

Based on 6 Wall Street analysts offering 12 month price targets forCareDx Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Buy

6 ratings

2

Buy

4

Hold

0

Sell

Technical Score

By Trading Central

14.77 / 18.49Support & Resistance

Short Term

Neutral Evidence

Intermediate Term

Strong Bearish Evidence

Long Term

Weak Bearish Evidence

Sentiment

By Acuity

110 / 348 Ranking in Healthcare

News Sentiment

Bullish Evidence

Volatility

Below average

News Volume (RCV)

Below average

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About CareDx Inc

CareDx, Inc. engages in the discovery, development, and commercialization of diagnostic solutions for transplant patients and caregivers in the United States and internationally. It also provides AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression solution for heart transplant patients; AlloSure Heart, a dd-cfDNA solution for heart transplant patients; and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. The company offers Olerup SSP, which is used to type human leukocyte antigen (HLA) alleles based on sequence specific primer technology; QTYPE that enables precision in HLA typing; and Ottr, a transplant patient management software. In addition, it provides AlloSeq Tx, a high-resolution HLA typing solution; AlloSeq cfDNA, a surveillance solution to measure dd-cfDNA in blood; AlloSeq HCT, a solution for chimerism testing for stem cell transplant recipients; Allocell, a surveillance solution that monitors the level of engraftment and persistence of allogeneic cells for patients who have received cell therapy transplants; and XynQAPI cloud-based transplant quality management software, as well as AlloCare, a mobile app that offers a patient-centric resource for transplant recipients. The company offers its products directly to customers, as well as through third-party distributors and sub-distributors. It has a license agreement with Illumina, Inc. for the distribution, development, and commercialization of NGS products and technologies; and Cibiltech SAS to commercialize iBox, a software for the predictive analysis of post-transplantation kidney allograft loss. The company was formerly known as XDx, Inc. and changed its name to CareDx, Inc. in March 2014. The company was incorporated in 1998 and is headquartered in South San Francisco, California.
help-icon Live chat